Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Sleep Cycle, Audiocast, Q2'26

By Inderes8/26/2026, 7:30 AM
Sleep Cycle

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Erik Jivmark
00:02 - 09:55

Good morning, everyone, and welcome to Sleep Cycle AB's second quarter earnings call. I'm Erik Jivmark. I'm the CEO, and I'm joined by Elisabeth Hedman, our CFO and Head of Investor Relations. So Q2 was a demanding quarter for the consumer business, but it was also a quarter where the strategic shift we have been building towards became increasingly tangible. So today, I want to spend most of my time on that shift. What is changing in our market, how we are broadening the business beyond the app and the progress we're seeing across the three growth pillars. But first, our mission. It has not changed. We want to improve global health by helping people take control of their sleep. What is changing, though, is how we scale that mission. We're moving beyond app stores. So Sleep Cycle starts from a position that is difficult to replicate. We have analyzed more than 4 billion nights of sleep. We have reached more than 82 million installs, and we have built a large active user base over more than a decade. And importantly, this was built largely through organic growth and also with a very efficient operating model. So when we talk about moving beyond the app, we're not starting a new business from scratch. We are leveraging our technology, data distribution, and sleep expertise that already exists. And we apply that in more ways, and thereby, we're taking control of our own destiny. So this chart explains where we are in the journey from 2021 to 2025. We built a highly profitable consumer business. Revenue grew, margins expanded, and B2B gradually became a larger part of the mix. 2026 is different. We are deliberately investing more heavily in new growth areas while the consumer business is under pressure. But we're funding that transformation from the business we have already built, and the objective is clear: from 2027 and onward, we want several growth engines rather than relying almost entirely on one consumer subscription product. That is the transition that we're making. And the reason why we can do that is because the underlying opportunity around sleep is broadening. Sleep is increasingly connected to health, performance, recovery, and even longevity, and therefore the way consumers experience sleep technology is also changing. It's moving into all the different spaces such as wearables, digital health, even pharma, smart home products, and broader health platforms. And those environments increasingly value exactly the type of technology we have built: passive sensing, continuous insights, and software that can operate in the background. So the important point is that the sleep opportunity is increasingly larger than the standalone sleep app category, where we have historically been operating. That also changes the market that we can address. Historically, we operated primarily in a sleep app market around 1.7 billion SEK. By applying the same underlying technology to sleep apnea and tech licensing. Our estimated addressable market expands to around 47 billion SEK annually. That is the structural change. So the same core technology, more use cases, more distribution channels, and much larger markets. So this brings us to the three pillars of the strategy. First, we have the Sleep Cycle app. It remains our consumer engine. It is our largest source of revenue and an important distribution platform. This is where the majority of our staff is focusing their time. Secondly, we have sleep apnea, where we want to apply our technology to a significantly larger medical need and a much larger market. And thirdly, we have tech licensing, where partners can embed the Sleep Cycle technology directly into their own products and ecosystems. What connects all these is the same underlying technology platform. And that is very important because we are not building three unrelated businesses. What we're doing is we're creating multiple routes to market from the capabilities we already have. I want to zoom in a little bit on each of these pillars, starting with the app. There is no other way to put it than the consumer business remains under pressure, particularly at the top of the funnel. Acquisition is the main challenge, but underneath the headline, there are several encouraging signals. We continue to gain download shares within the Meditation and Sleep Tracker segment on iOS. Pricing has held up. We have an FX-adjusted ARPU of 286. We also see that engagement is improving. We have a threefold increase in sleep aid usage. Let me mention one thing, we are starting to build distribution outside the traditional App Store funnel. So web to app is still small, but conversion and monetization are moving materially in the right direction. So the diagnosis is very straightforward. We need to rebuild acquisition. But the underlying product economics and also the engagement give us something to build from. Turning to sleep apnea. Before we go into the details of the program, I think it's worth keeping the opportunity in mind. So sleep apnea is a very large and highly undiagnosed condition. Traditional diagnostic pathways are expensive and difficult to scale. Our ambition is to make risk detection significantly more accessible through a software-only approach. 150,000 people who have already signed up and registered interest give us an indication that there is a real consumer demand ahead of launch. And the same goes for B2B, where we have a lot of interesting conversations right now with potential partners. But let's talk a little bit about the clinical validation study. So the original study itself has been executed essentially as planned. The challenge is that fewer participants than expected have turned out to have moderate to severe OSA. Importantly, participants cannot be recruited based on a previously known sleep apnea diagnosis. So we only know the clinical mix after the study nights have been completed. We do not know it beforehand. As a result, we need to find more people that have moderate to severe OSA. Therefore, additional enrollment is required to secure the statistical basis for the regulatory approval, which will require a materially larger investment and shift the timeline. The newly appointed board is currently preparing the decision on the scope of the extension. Our ambition to achieve regulatory approval in the US remains unchanged. We will, of course, communicate an updated timeline once the decision has been taken. It's also important to separate the need for additional enrollment from the broader regulatory program. We have achieved a number of significant milestones in this quarter. We have external specialists who have been validating the regulatory approach that we are taking. The quality system is being established against the relevant standards. The documentation has passed an external audit and the design phase is done. So the work is now about completing the required clinical evidence that we need. The dates beyond Q2. You should see those as preliminary. And it depends, of course, on the board's decision and the pace of recruitment, but our ambition remains US regulatory approval during 2027. Finally, tech licensing. This is where we are increasingly moving from platform development to commercial adaptation. We now have a broad set of partner-ready capabilities, and these capabilities can be embedded across a wide range of partner ecosystems. And I think, more importantly, we have commercial proof after the quarter. Ultrahuman converted their pilot into a commercial SDK license. We started an SDK pilot with Ant Group. This gives us an entry into the Chinese market, and our global IoT agreement starts to contribute revenue now in Q3. We have also completed the UKHSA research and the collaboration we had there around cough data. So this is increasingly becoming a real commercial business, not a strategic pipeline. And with that, I'll hand over to Elisabeth to take you through the financial performance.

Elisabeth Hedman
09:57 - 15:35

Thank you, Erik. So let me take you through the quarter in numbers. I'll keep this to the headlines and come back to the details on the slides that follow. Net sales were just under 50 million SEK, down around 20% reported and around 15% currency-adjusted; EBIT was -7.5 million SEK. And that figure carries close to 11 million SEK of items affecting comparability. Comparability-adjusted EBIT was positive at 3.4 million SEK, a margin of nearly 7%. Paying subscribers ended the quarter at 665,000, against 878,000 a year ago. ARPU was 257 SEK reported, but 286 SEK currency-adjusted. The B2B revenue grew close to 30% year-over-year and now accounts for around 15% of the total revenue. And we ran the quarter with 38 employees on average. So that is the shape of the quarter. We have a top line under pressure, a mix moving in the right direction, and a deliberate investment profile. So, I'll take you through the mix. The bridge to adjusted EBIT and the cash position on the next few slides. So this slide is the single best picture of the transformation. The B2B share of revenue has gone from around 5% to 15% in nine quarters. That is roughly a tripling of the B2B revenue, which was broadly flat this quarter against the previous quarter. And the reason is specific. We renegotiated our agreement with Ultrahuman during this quarter, and the pilot was converted into a commercial licensing agreement. So we had a temporary pause on the revenue. Year over year, the B2B revenue grew close to 30%, compared to a 9% share a year ago. And on the signed agreement we have, we expect the B2B revenue to come in above 9 million SEK in the third quarter. On the consumer side, the currency-adjusted ARPU was 286 SEK against 257 SEK reported and 269 SEK last year. And that gap is the whole story. Currency is the headwind, not the willingness to pay. So our price increases are showing through in the FX-adjusted figures. So while the reported top line is down, the mix underneath is shifting towards the recurring higher leverage B2B revenue that we have been building for. Now to the financials in a bit more detail and what sits behind the numbers. Starting with the currency, around six percentage points of the reported decline is due to exchange rates, not lost business. So currency-adjusted, the decline is around 15% rather than 20%. And it is worth being precise about where the rest of it sits. It is in the new B2B sales. It is not within retention. Renewal and pricing are holding up. The pressure is at the top of the acquisition funnel. Against that, B2B grew close to 30% year-over-year, with an increasing share of it recurring sequentially. It was broadly flat for the reason I mentioned on the previous slide, but the year-over-year trend is the one that matters here. On costs. The reported lines in the table carry the items affecting comparability. Close to 9 million SEK of transaction costs for the offer sits in other external costs, and just over 2 million SEK for the reorganization sits in personnel, excluding those which is the like-for-like comparison. The cost base is still up and that is deliberate. The technology platform and the partnership business, and the other side of the margin, is simply the top line. The revenue that we lost is B2C and that shortfall weighs directly on the margin. So the reported EBIT margin was -15%, and the adjusted margin was close to 7%. And the difference between those two is the items affecting comparability, the offer, and the reorganization. I will show you a bridge on the next slide. So here is the bridge. We start at -7.5 million reported. We add back around 9 million in transaction costs related to the public cash offer, and just over 2 million in reorganization costs, totaling close to 11 million of items affecting comparability between the quarters. That takes us to an adjusted EBIT of positive 3 million, with a margin of nearly 7%. The point I want to leave with you is that both items are non-recurring and separately identifiable. Identifiable. This is not a redefinition of the underlying cost base. The costs are related to these two items. On cash, the headline is that operations still generate cash. During this quarter, we paid a dividend to shareholders and we invested primarily within Sleep Apnea. That is why the cash flow is reflected this way. It is all funded internally. We have no debt, so we do not expect to need external capital while still returning capital to shareholders. So the investment program itself is fully self-funded. And with that, let me hand back to Erik to take you through the medium-term targets and what the sleep apnea licensing opportunities look like from here. Erik.

Erik Jivmark
15:36 - 18:18

All right. Thanks, Elisabeth. So our medium-term ambition is unchanged. And I want to say that clearly, given the quarter we just reported, on capital return, 40 to 60% of profit after tax are paid out to shareholders. The dividend of 0.53 SEK per share for the 2025 financial year was approved at the AGM on the 13th of April 2026. On growth, we retain the ambition to double revenue over the medium term. It is driven primarily by B2B, sleep apnea, and tech licensing. On profitability, an EBIT margin of at least 25% per year. And that should be measured through the cycle. So these are through-cycle targets. And Q2 sits below the profitability level. And as you notice, there are also a lot of items affecting comparability. However, the targets reflect where we expect the business to operate once the B2B ramp-up and the investment phase are behind us. I just want to close with the outlook. So the picture for the second half is relatively clear. We still expect full-year revenue to decline, but we expect the rate of decline to moderate in the second half as B2B revenue grows from agreements that are already signed into converting to revenue in Q3. We expect B2B revenue to exceed 9 million SEK. That would represent around a 30% year-on-year growth. And that is before we add any new contributions from contracts that we haven't yet signed. On profitability, we continue to expect a reported EBIT margin of around 5% for the full year, with an adjusted margin around 9%, and on sleep apnea. Our ambition for U.S. Regulatory approval in 2027 remains unchanged. The next step is that the board will decide on the scope of the study and the extension of the study. So, despite the challenging consumer environment, the direction of travel is crystal clear for us. The decline should moderate, B2B is becoming a more meaningful contributor, and we continue to invest behind opportunities that we believe can drive the next phase of growth. And with that, Elisabeth and I are happy to take any questions that you might have.

Elisabeth Hedman
18:22 - 18:45

All right. So let's see. We have a question from Jessica Grunewald at Redeye regarding the sleep apnea study needing expansion for statistical significance. Was this a design flaw in the original study or a population enrollment issue? And does it change your confidence in the underlying technology's clinical performance?

Erik Jivmark
18:46 - 20:03

It's a very good question. And I think this is the irony of everything. So the study that we have done, we carried out on time. The challenge we have is that we do not know before someone takes the test if they have moderate to severe Sleep Apnea or not, and to file for the approval to the FDA, we need two buckets of people. So one bucket of people that has been sleeping and turns out not to have sleep apnea. That bucket is full. The other bucket is people that have moderate to severe sleep apnea. There, we lack a number of subjects to be able to file for the approval to FDA. So we are, and this is where it becomes a little bit counterintuitive. The study has been carried out according to plan and on time. We started in April and we finalized it. We are wrapping it up. In these days, the challenge we have had—and I have no other way to put it—is that we have been a bit unlucky in the distribution of the people who have been sleeping. So that's what we need to do. It hasn't changed my confidence in the underlying technology one bit.

Elisabeth Hedman
20:06 - 20:26

Okay, so another question from Jessica. Now that Arkwright holds 78.2% of the votes. And now the new board is seated. How has your day-to-day mandate as CEO changed, with more autonomy, tighter reporting lines, or a shift in strategic priorities from the previous board?

Erik Jivmark
20:27 - 20:46

Well, I think it is too early to answer. I mean, currently we are in onboarding mode with a new board, and we will see further on how things potentially might shift, but right now we are onboarding, and there is no real change from the previous situation.

Elisabeth Hedman
20:48 - 21:06

We have also one question from another person; given Ant Group's scale, should we think of the one-year agreement primarily as a technology validation, or is there already a clear path to meaningful recurring revenue if the pilot performs well?

Erik Jivmark
21:07 - 22:20

It's a very good question. So the pilot is, of course, for them to validate that there is a relevant use case for the technology that we are offering them. We have a commercial agreement for the pilot that does not make a big dent in our top line, but there is at least something. And because that's very important for us, we don't just want to give away technology that's not a commercial model. So we will, during the pilot, also discuss with them what the next step would be. It is a very similar approach to the one we took with Ultrahuman, and the positive news regarding the pilot is that Ant Group is a very big player in the region where we are currently in dialogues with other B2B tech licensing partners. It is not insignificant that we have signed Ant Group and Ofo. It means quite a lot for the other conversations that we have, and that is why we were really eager to get this over the finish line.

Elisabeth Hedman
22:23 - 22:25

All right. So those were all the questions.

Erik Jivmark
22:25 - 22:26

All right.

Elisabeth Hedman
22:26 - 22:26

Thank you so much.

Erik Jivmark
22:26 - 22:27

Thank you very much.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…